SEC Filing Summary: Amedica Corporation (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Amedica Corporation on September 11, 2015. The report details the closing of previously announced public and private offerings of common stock and Series A, Series B, and Series C Warrants. Note: The request metadata references "Sintx Technologies, Inc.", but the filing text explicitly identifies the registrant as Amedica Corporation.
Key Financial Metrics
- Gross Proceeds: Approximately $5.0 million received from the offerings before placement agent fees and related expenses.
- Debt and Liquidity: The filing does not provide specific data on existing debt levels, cash flow, or liquidity ratios beyond the proceeds from this transaction.
- Revenue and Profit: No revenue, profit, or margin data is included in this specific filing.
Material Changes
The primary material change is the successful closing of the capital raise, resulting in an influx of approximately $5.0 million in gross proceeds. Additionally, the Company entered into "Leak-Out Agreements" with participating investors to restrict the sale of newly issued shares.
Guidance, Outlook, and Restrictions
Leak-Out Agreements: Investors are restricted from selling more than the greater of 5,000 shares or 8% of the daily average composite trading volume until November 13, 2015, unless specific conditions are met.
Exemption Conditions: The selling restrictions do not apply if shares are sold at a price of $0.50 or higher and the last reported price on the principal trading market is at or above $0.50.
Outlook and Risks: The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the terms of the Leak-Out Agreements.
Key Facts for Investor Verification
- Verify the net proceeds after deducting placement agent fees and related expenses, as only gross proceeds ($5.0 million) are disclosed.
- Confirm the total number of shares and warrants issued in the offering to assess dilution impact.
- Review the full text of the Leak-Out Agreement (Exhibit 10.1) for specific conditions that may alter the restriction period or volume limits.
- Check subsequent filings for the actual use of proceeds and any impact on the company's cash position.